Recurrent Mycosis Fungoides Recruiting Phase 1 / 2 Trials for Durvalumab (DB11714)

Also known as: Mycosis fungoides recurrent

IndicationStatusPhase
DBCOND0080283 (Recurrent Mycosis Fungoides)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03011814Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaTreatment